The global sensory organ drugs market size was valued at USD 23.74 billion in 2020 and is expected to expand at a compound annual growth (CAGR) of 5.5% from 2021 to 2028. Diseases of eyes and ears among the population across the world are increasing due to the factors, such as increasing air and sound pollution levels, nervous disorders, age-related degeneration of sensory organs, improper and insufficient diet, and hereditary disorders. With increasing cases of disorders and diseases of eyes and ears, the demand for sensory organ drugs for their treatment is also increasing. Moreover, the growing awareness about disorders and diseases, availability of detection devices, and increasing demand for rapid diagnosis are also contributing to the market growth.
Sensory organs include eyes and ears. Diseases and disorders related to eyes and ears can be diagnosed and cured using ophthalmological and otological treatments and related drugs. These drugs are majorly available in drop or injection forms. Depending upon the symptoms and test results, medical practitioners prescribe the most appropriate treatment to improve the functioning of the eye or ear. Early identification of disease or disorder is the key to effective disease management. During the COVID-19 pandemic, the governments of various countries restricted physical movement and citizens preferred to stay at home as a precautionary measure. This affected the supply chains of oncology. Considering urgency and emergency, the supply of drugs was allowed by governments. Thus, a negligible impact of the pandemic is observed on the market revenue.
The eyes segment dominated the market with a revenue share of more than 64.0% in 2020 and is expected to grow at the fastest growth rate from 2021 to 2028. The eyes are the most delicate sensory organ of the human body. The major leading cause of eye-related disorders, such as impairment and blindness, are uncorrected refractive errors and cataracts. Vision loss can be observed among all age groups. With growing cases of eye diseases and disorders, a number of innovative therapies are being developed. This is contributing to the market revenue and segment growth.
On the basis of organs, the global market has been further segmented into eyes and ears. The ears segment accounted for a significant revenue share in 2020. Compared to eye diseases, the number of patients with diseases and disorders of the ears is fewer. Major causes of ear disorders and diseases include nutritional deficiencies, viral and other ear infections, the impact of loud noise, and progressive genetic hearing loss. With systematic screening for detection, disorders and diseases of ears can be cured with Otologicals treatments and drugs.
On the basis of geographies, the global market has been further divided into North America, Asia Pacific, Europe, Middle East & Africa, and Central & South America. Asia Pacific is likely to expand at the fastest growth rate of more than 6.5% from 2021 to 2028. Countries with high populations, such as China and India, are expected to have a large number of patients with sensory diseases over the forecast period. Continuous improvement of the life science industry & health services and awareness about skin diseases & their treatments are factors contributing to the growth of this segment.
Moreover, increasing income levels and purchasing power of citizens are driving the segment growth. Europe accounted for the second-largest revenue share in 2020 and is expected to grow further at a steady CAGR over the forecast period. Factors, such as increasing healthcare expenditure, rising R&D investments in the healthcare sector, greater prevalence of healthcare insurance among the masses, and supportive regulatory frameworks of the pharmaceutical industry, in this region, are attributed to the regional market growth.
The market is characterized by the presence of various well-established players and several small- and medium-scale players. Pharmaceutical vendors are focusing on research activities to launch new chemical formulae of drugs. Moreover, pharmaceutical vendors are expanding their reach across the globe to increase revenues. Such initiatives are expected to boost product adoption. The vendors are aggressively following organic as well as inorganic strategies to enhance and strengthen their market position. Some of the prominent players in the global sensory organs drug market include:
Report Attribute |
Details |
Market size value in 2021 |
USD 24.71 billion |
Revenue forecast in 2028 |
USD 35.84 billion |
Growth rate |
CAGR of 5.5% from 2021 to 2028 |
Base year for estimation |
2020 |
Historical data |
2017 - 2019 |
Forecast period |
2021 - 2028 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2021 to 2028 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Organ and region |
Regional scope |
North America; Europe; Asia Pacific; Central & South America; Middle East & Africa |
Country scope |
U.S.; Germany; France; U.K.; China; India; Brazil; South Africa |
Key companies profiled |
Johnson & Johnson; Merck KGaA; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Pfizer Inc.; GlaxoSmithKline Plc; AstraZeneca plc; Eli Lilly And Company; Amgen Inc.; Novartis AG |
Customization scope |
Free report customization (equivalent up to 8 analysts’ working days) with purchase. Addition or alteration to country, regional & segment scope. |
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For the purpose of this study, Million Insights has segmented the global sensory organ drug market report on the basis of organ and region:
Sign up today.
Call us at +1-408-610-2300 to speak with a
representative.